Our international R&D center (“Ribocure AB”) was established in January, 2022 in Gothenburg, Sweden, which is our global clinical development and business development base, with a professional team that has an international vision and global clinical development strength. Ribocure AB has biology laboratories and clinical trial sites that lead and drive clinical trials and commercial development of innovative oligonucleotide drugs around the world.
